未知机构：创新药观点更新20260304BD频出再次验证此前关于国-20260304

Summary of Conference Call Notes Industry Overview - The focus is on the innovative pharmaceutical industry in China, particularly the progress of domestic companies in early-stage research compared to their Western counterparts [1] Key Points and Arguments - There is a growing trend of domestic innovative drugs catching up and potentially surpassing Western innovations in early research stages, as evidenced by recent business development (BD) activities [1] - Recent announcements from China Biologic Products and Deqi Pharmaceuticals regarding partnerships with Sanofi and UCB highlight the ongoing progress in the industry [1] - The CD3/CD19 dual-target antibody from Deqi is already in the early research phase and is being marketed internationally, indicating a significant advancement in the sector [1] - The upcoming AACR conference in April and the ASCO conference mid-year are expected to provide further insights and updates on the industry [1] - Despite potential fluctuations in BD optimism, the industry is expected to continue benefiting from ongoing BD contributions, reinforcing the growth potential of the sector [1] - The global participation of innovative drugs from China has been increasingly evident since 2025, suggesting a positive outlook for domestic new drugs in the mid-term [1] - The expectation is that domestic innovative drugs will enter a harvest period due to efficiency-driven competition, making it a promising investment opportunity [1] Additional Important Content - Recommendations for high-certainty stocks with relatively low BD disruption include: Innovent Biologics, 3SBio, Kangfang Biopharmaceuticals, Ying'en Biopharmaceuticals, Vila Biotech, Lepu Biopharma, and Kangnuo Pharmaceuticals [2] - Attention is also drawn to new technology sectors such as small nucleic acids, with companies like Frontier Biotech, Sunshine Nuohuo, and upstream supply chain firms like Aorite, Lanshan Technology, Nami Technology, and Jiuzhou Pharmaceutical being highlighted [2]